Q4 2023 · 13F-HR
DAFNA Capital Management LLCholdings as filed
Filed 2024-02-14 · accession 0001389932-24-000004
$417.3M
Reported value
76
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 78464A870 | XBI | SPDR S&P BIOTECH ETF | $43.2M | 10.4% | 484,000 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $33.4M | 8.00% | 400,000 | Common | SOLE |
| 85916J409 | STXS | STEREOTAXIS INC | $23.9M | 5.74% | 13,680,554 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $18.4M | 4.40% | 516,341 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $16.0M | 3.85% | 742,574 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $15.6M | 3.73% | 123,472 | Common | SOLE |
| 48576A100 | — | KARUNA THERAPEUTICS INC | $15.2M | 3.65% | 48,145 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $14.7M | 3.52% | 511,894 | Common | SOLE |
| 464287556 | IBB | ISHARES NASDAQ BIOTECH INDX | $13.9M | 3.34% | 102,500 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $12.7M | 3.05% | 276,739 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $12.5M | 3.00% | 454,870 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $10.2M | 2.45% | 110,863 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $10.0M | 2.40% | 686,463 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $9.6M | 2.29% | 72,615 | Common | SOLE |
| 252131107 | DXCM | DEXCOM INC | $8.4M | 2.01% | 67,552 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $7.4M | 1.76% | 601,032 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $7.2M | 1.73% | 168,772 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $7.1M | 1.70% | 492,684 | Common | SOLE |
| 61775R105 | MORFUSD | MORPHIC HOLDING INC | $6.7M | 1.60% | 231,748 | Common | SOLE |
| 875372203 | TNDM | TANDEM DIABETES CARE INC | $6.5M | 1.56% | 220,708 | Common | SOLE |
| 05463X106 | AXGN | AXOGEN INC | $6.4M | 1.53% | 935,894 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $6.2M | 1.48% | 1,447,465 | Common | SOLE |
| 45253H101 | IMGNEUR | IMMUNOGEN INC | $5.7M | 1.38% | 193,661 | Common | SOLE |
| 78667J108 | SG7 | SAGE THERAPEUTICS INC | $5.3M | 1.27% | 245,000 | Common | SOLE |
| 36315X101 | LKFT | GALAPAGOS NV | $5.3M | 1.27% | 130,175 | Common | SOLE |
| 60468T105 | MRTXEUR | MIRATI THERAPEUTICS INC | $5.3M | 1.26% | 89,387 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $4.9M | 1.18% | 449,384 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $4.9M | 1.17% | 609,905 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $4.6M | 1.11% | 248,217 | Common | SOLE |
| 04963C209 | ATRC | ATRICURE INC | $4.5M | 1.07% | 125,529 | Common | SOLE |
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $4.4M | 1.07% | 232,717 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $4.3M | 1.04% | 1,307,407 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $4.2M | 1.02% | 709,500 | Common | SOLE |
| 04351PAD3 | ASND 2.25 04/01/28 | ASCENDIS PHARMA A/S | $4.1M | 0.99% | 4,000,000 | Common | SOLE |
| 004397105 | ARAY | ACCURAY INC | $3.5M | 0.83% | 1,222,358 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $3.4M | 0.83% | 449,008 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $3.0M | 0.71% | 74,361 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $2.8M | 0.66% | 371,200 | Common | SOLE |
| 74276L105 | PRCT | PROCEPT BIOROBOTICS CORP | $2.7M | 0.64% | 63,300 | Common | SOLE |
| M68830112 | MDWD | MEDIWOUND LTD | $2.6M | 0.63% | 257,653 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $2.2M | 0.53% | 122,200 | Common | SOLE |
| 10501L106 | BWAY | BRAINSWAY LTD | $2.0M | 0.48% | 308,471 | Common | SOLE |
| N71542109 | PRQR | PROQR THERAPEUTICS N V | $1.9M | 0.45% | 940,582 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $1.8M | 0.43% | 122,547 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $1.8M | 0.43% | 778,813 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $1.7M | 0.41% | 40,742 | Common | SOLE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $1.7M | 0.41% | 311,169 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $1.7M | 0.40% | 193,000 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $1.7M | 0.40% | 214,885 | Common | SOLE |
| 85209E109 | — | SPRUCE BIOSCIENCES INC | $1.6M | 0.39% | 548,510 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $1.5M | 0.35% | 323,873 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $1.5M | 0.35% | 152,250 | Common | SOLE |
| 75915K309 | RGLS | REGULUS THERAPEUTICS INC | $1.4M | 0.34% | 1,111,049 | Common | SOLE |
| 04016X101 | ARGX | ARGEN SE | $1.4M | 0.33% | 3,600 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $1.3M | 0.32% | 1,476,052 | Common | SOLE |
| 230031106 | CGEM | CULLINAN ONCOLOGY INC | $1.3M | 0.31% | 127,284 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $1.2M | 0.29% | 191,070 | Common | SOLE |
| 869367102 | — | SUTRO BIOPHARMA INC | $1.2M | 0.29% | 283,079 | Common | SOLE |
| N44445109 | IMTX | IMMATICS NV | $1.1M | 0.26% | 105,000 | Common | SOLE |
| 46565G104 | 5E7 | ITEOS THERAPEUTICS INC | $1.1M | 0.26% | 98,560 | Common | SOLE |
| 64131A105 | STIM | NEURONETICS INC | $909,779 | 0.22% | 313,717 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $669,732 | 0.16% | 72,797 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $646,247 | 0.15% | 131,351 | Common | SOLE |
| 64157F103 | NVROEUR | NEVRO CORP | $602,560 | 0.14% | 28,000 | Common | SOLE |
| M25722105 | CGEN | COMPUGEN LTD | $406,300 | 0.10% | 205,202 | Common | SOLE |
| 574795100 | MASI | MASIMO CORP | $351,630 | 0.08% | 3,000 | Common | SOLE |
| 00653A107 | ADAPY | ADAPTIMMUNE THERAPEUTICS PLC | $278,394 | 0.07% | 351,064 | Common | SOLE |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $242,735 | 0.06% | 71,815 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $241,650 | 0.06% | 450,000 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $215,294 | 0.05% | 41,886 | Common | SOLE |
| 84833T103 | SPRO | SPERO THERAPEUTICS INC | $183,750 | 0.04% | 125,000 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $182,336 | 0.04% | 116,882 | Common | SOLE |
| 48576U106 | KPTIEUR | KARYOPHARM THERAPEUTICS INC | $166,666 | 0.04% | 192,678 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $130,720 | 0.03% | 15,200 | Common | SOLE |
| 49705R105 | KNTEUSD | KINNATE BIOPHARMA INC | $118,500 | 0.03% | 50,000 | Common | SOLE |
| 45780L104 | INGN | INOGEN INC | $82,350 | 0.02% | 15,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.